{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:08:56Z","timestamp":1788473336667,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,1,4]],"date-time":"2013-01-04T00:00:00Z","timestamp":1357257600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2013,1,4]],"date-time":"2013-01-04T00:00:00Z","timestamp":1357257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The aim of this study was to explore the persistence of an antibody response 1.5 years after vaccination with 7-valent pneumococcal conjugate vaccine in patients with rheumatoid arthritis (RA) or spondyloarthropathy (SpA) treated with different antirheumatic drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Of 505 patients initially recruited, data on current antirheumatic treatment and blood samples were obtained from 398 (79%) subjects after mean (SD, range) 1.4 (0.5; 1 to 2) years. Antibody levels against pneumococcal serotypes 23F and 6B were analyzed by using enzyme-linked immunosorbent assay (ELISA). Original treatment groups were as follows: (a) RA receiving methotrexate (MTX); (b) RA taking anti-TNF monotherapy; (c) RA taking anti-TNF+MTX; (d) SpA with anti-TNF monotherapy; (e) SpA taking anti-TNF+MTX; and (f) SpA taking NSAID\/analgesics. Geometric mean levels (GMLs; 95% CI) and proportion (percentage) of patients with putative protective antibody levels \u22651 mg\/L for both serotypes, calculated in different treatment groups, were compared with results 4 to 6 weeks after vaccination. Patients remaining on initial treatment were included in the analysis. Possible predictors of persistence of protective antibody response were analysed by using logistic regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 398 patients participating in the 1.5-year follow up, 302 patients (RA, 163, and SpA, 139) had unchanged medication. Compared with postvaccination levels at 1.5 years, GMLs for each serotype were significantly lower in all groups (\n                      <jats:italic>P<\/jats:italic>\n                      between 0.035 and &lt;0.001; paired-sample\n                      <jats:italic>t<\/jats:italic>\n                      test), as were the proportions of patients with protective antibody levels for both serotypes (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001; \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      test). Higher prevaccination antibody levels for both serotypes 23F and 6B were associated with better persistence of protective antibodies (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). Compared with patients with protective antibody levels at 1.5 years, those not having protective antibody levels were older, more often women, had longer disease duration and higher HAQ and DAS, and had a lower proportion of initial responders to both serotypes.\n                    <\/jats:p>\n                    <jats:p>\n                      Concomitant anti-TNF treatment and MTX were identified as negative predictors of the persistence of protective antibodies among RA patients (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.024 and\n                      <jats:italic>P<\/jats:italic>\n                      = 0.065, respectively). Only age 65 years or older (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.017) and not antirheumatic treatment was found to be a negative predictor of protective antibodies in patients with SpA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>After initial increase, 1.5 years after pneumococcal vaccination with 7-valent conjugate vaccine, postvaccination antibody levels decreased significantly, reaching levels before vaccination in this cohort of patients with established arthritis treated with different antirheumatic drugs. MTX and anti-TNF treatment predicted low persistence of protective immunity among patients with RA. To boost antibody response, early revaccination with conjugate vaccine might be needed in patients receiving potent immunosuppressive remedies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      EudraCT EU 2007-006539-29 and\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00828997\">NCT00828997<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/ar4127","type":"journal-article","created":{"date-parts":[[2013,1,4]],"date-time":"2013-01-04T04:14:08Z","timestamp":1357272848000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs"],"prefix":"10.1186","volume":"15","author":[{"given":"Meliha","family":"Crnkic Kapetanovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore","family":"Saxne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Truedsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Geborek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,4]]},"reference":[{"key":"3860_CR1","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1136\/ard.2006.057265","volume":"66","author":"J Franklin","year":"2007","unstructured":"Franklin J, Lunt M, Bunn D, Symmons D, Silman A: Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis. 2007, 66: 308-312. 10.1136\/ard.2006.057265. Epub 2006 Sep 19","journal-title":"Ann Rheum Dis"},{"key":"3860_CR2","first-page":"1832","volume":"34","author":"P Coyne","year":"2007","unstructured":"Coyne P, Hamilton J, Heycock C, Saravanan V, Coulson E, Kelly CA: Acute lower respiratory tract infections in patients with rheumatoid arthritis. J Rheumatol. 2007, 34: 1832-1836.","journal-title":"J Rheumatol"},{"key":"3860_CR3","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1002\/art.10524","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE : Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002, 46: 2287-2293. 10.1002\/art.10524.","journal-title":"Arthritis Rheum"},{"key":"3860_CR4","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1002\/art.10529","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE: Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002, 46: 2294-2300. 10.1002\/art.10529.","journal-title":"Arthritis Rheum"},{"key":"3860_CR5","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/rheumatology\/kep101","volume":"48","author":"A McLean-Tooke","year":"2009","unstructured":"McLean-Tooke A, Aldridge C, Waugh S, Spickett GP, Kay L: Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?. Rheumatology (Oxford). 2009, 48: 867-871. 10.1093\/rheumatology\/kep101.","journal-title":"Rheumatology (Oxford)"},{"key":"3860_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.autrev.2010.12.003","volume":"10","author":"S van Assen","year":"2011","unstructured":"van Assen S, Elkayam O, Agmon-Levin N, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JP, Jayne DR, Kallenberg CG, M\u00fcller-Ladner U, Shoenfeld Y, Stojanovich L, Valesini G, Wulffraat NM, Bijl M: Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev. 2011, 10: 341-352. 10.1016\/j.autrev.2010.12.003.","journal-title":"Autoimmun Rev"},{"key":"3860_CR7","first-page":"1102","volume":"59","author":"Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices","year":"2010","unstructured":"Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices: Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR. 2010, 59: 1102-1106.","journal-title":"MMWR"},{"key":"3860_CR8","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1093\/rheumatology\/keq297","volume":"50","author":"SP Desai","year":"2011","unstructured":"Desai SP, Turchin A, Szent-Gyorgyi LE, Weinblatt M, Coblyn J, Solomon DH, Kachalia A: Routinely measuring and reporting pneumococcal vaccination among immunosuppressed rheumatology outpatients: the first step in improving quality. Rheumatology (Oxford). 2011, 50: 366-372. 10.1093\/rheumatology\/keq297.","journal-title":"Rheumatology (Oxford)"},{"key":"3860_CR9","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1136\/ard.2010.144451","volume":"70","author":"E Coulson","year":"2011","unstructured":"Coulson E, Saravanan V, Hamilton J, Long KS, Morgan L, Heycock C, Rynne M, Kelly C: Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. Ann Rheum Dis. 2011, 70: 1289-1291. 10.1136\/ard.2010.144451. Epub 2011 Apr 22","journal-title":"Ann Rheum Dis"},{"key":"3860_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/rheumatology\/kei193","volume":"45","author":"MC Kapetanovic","year":"2006","unstructured":"Kapetanovic MC, Saxne T, Sj\u00f6holm A, Truedsson L, J\u00f6nsson G, Geborek P: Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006, 45: 106-111. 10.1093\/rheumatology\/kei193.","journal-title":"Rheumatology (Oxford)"},{"key":"3860_CR11","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1002\/art.30580","volume":"63","author":"MC Kapetanovic","year":"2011","unstructured":"Kapetanovic MC, Roseman C, J\u00f6nsson G, Truedsson L, Saxne T, Geborek P: Methotrexate but not TNF-blockers reduces antibody response following pneumococcal vaccination using 7-valent conjugate pneumococcal vaccine in adult patients with established arthritis. Arthritis Rheum. 2011, 63: 3723-3732. 10.1002\/art.30580.","journal-title":"Arthritis Rheum"},{"key":"3860_CR12","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin SA: Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010, 17: 1055-1065. 10.1128\/CVI.00131-10.","journal-title":"Clin Vaccine Immunol"},{"key":"3860_CR13","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1093\/infdis\/136.Supplement.S43","volume":"136","author":"PH M\u00e4kel\u00e4","year":"1977","unstructured":"M\u00e4kel\u00e4 PH, Peltola H. Kayhty H, Jousimies H, Pettay O, Ruoslahti E, Sivonen A, Renkonen OV: Polysaccharide vaccines of group A Neisseria meningitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis. 1977, 136: S43-S50. 10.1093\/infdis\/136.Supplement.S43.","journal-title":"J Infect Dis"},{"key":"3860_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/00365540050165929","volume":"32","author":"J Hedlund","year":"2000","unstructured":"Hedlund J, Ortqvist A, Konradsen HB, Kalin M: Recurrence of pneumonia in relation to the antibody response after pneumococcal vaccination in middle-aged and elderly adults. Scand J Infect Dis. 2000, 32: 281-286. 10.1080\/00365540050165929.","journal-title":"Scand J Infect Dis"},{"key":"3860_CR15","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1086\/516521","volume":"176","author":"U Sankilampi","year":"1997","unstructured":"Sankilampi U, Honkanen PO, Bloigu A, Leinonen M: Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis. 1997, 176: 1100-1104. 10.1086\/516521.","journal-title":"J Infect Dis"},{"key":"3860_CR16","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1086\/649839","volume":"201","author":"DM Musher","year":"2010","unstructured":"Musher DM, Manof SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, Alvarez F, Painter C, Blum MD, Silber JL: Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis. 2010, 201: 516-524. 10.1086\/649839.","journal-title":"J Infect Dis"},{"key":"3860_CR17","first-page":"306","volume":"11","author":"E McDonald","year":"1984","unstructured":"McDonald E, Jarrett MP, Schiffman G, Grayzel AI: Persistence of pneumococcal antibodies after immunization in patients with systemic lupus erythematosus. J Rheumatol. 1984, 11: 306-308.","journal-title":"J Rheumatol"},{"key":"3860_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1128\/CVI.00336-06","volume":"14","author":"M Chen","year":"2007","unstructured":"Chen M, Hisatomi Y, Furumoto A, Kawakami K, Masaki H, Nagatake T, Sueyasu Y, Iwanaga T, Aizawa H, Oishi K: Comparative immune responses of patients with chronic pulmonary diseases during the 2-year period after pneumococcal vaccination. Clin Vaccine Immunol. 2007, 14: 139-145. 10.1128\/CVI.00336-06.","journal-title":"Clin Vaccine Immunol"},{"key":"3860_CR19","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0264-410X(99)00240-6","volume":"18","author":"FP Kroon","year":"1999","unstructured":"Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R: Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine. 1999, 18: 524-530. 10.1016\/S0264-410X(99)00240-6.","journal-title":"Vaccine"},{"key":"3860_CR20","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1600-6143.2007.01668.x","volume":"7","author":"D Kumar","year":"2007","unstructured":"Kumar D, Welsh B, Siegal D, Chen MH, Humar A: Immunogenicity of pneumococcal vaccine in renal transplant recipients: three-year follow-up of a randomized trial. Am J Transplant. 2007, 7: 633-638. 10.1111\/j.1600-6143.2007.01668.x.","journal-title":"Am J Transplant"},{"key":"3860_CR21","first-page":"514","volume":"10","author":"CM Wernette","year":"2003","unstructured":"Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, Benjamin W, Quataert SA, Hildreth S, Sikkema DJ, K\u00e4yhty H, Jonsdottir I, Nahm MH: Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol. 2003, 10: 514-519.","journal-title":"Clin Diagn Lab Immunol"},{"key":"3860_CR22","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.maturitas.2011.01.011","volume":"68","author":"PO Lang","year":"2011","unstructured":"Lang PO, Govind S, Michel JP, Aspinall R, Mitchell WA: Immunosenescence: implications for vaccination programmes in adults. Maturitas. 2011, 68: 322-330. 10.1016\/j.maturitas.2011.01.011.","journal-title":"Maturitas"},{"key":"3860_CR23","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.rmed.2004.04.012","volume":"98","author":"A de Roux","year":"2004","unstructured":"de Roux A, Schmidt N, Rose M, Zielen S, Pletz M, Lode H: Immunogenity of the pneumococcal polysaccharide vaccine in COPD patients: the effect of systemic steroids. Respir Med. 2004, 98: 1187-1194. 10.1016\/j.rmed.2004.04.012.","journal-title":"Respir Med"},{"key":"3860_CR24","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1128\/IAI.67.11.5979-5984.1999","volume":"67","author":"JB Rubins","year":"1999","unstructured":"Rubins JB, Alter M, Loch J, Janoff EN: Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect Immun. 1999, 67: 5979-5984.","journal-title":"Infect Immun"},{"key":"3860_CR25","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1007\/s10067-011-1856-5","volume":"30","author":"MC Kapetanovic","year":"2011","unstructured":"Kapetanovic MC, Roseman C, J\u00f6nsson G, Truedsson L: Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs. Clin Rheumatol. 2011, 30: 1555-1561. 10.1007\/s10067-011-1856-5.","journal-title":"Clin Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar4127\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T06:49:28Z","timestamp":1728370168000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar4127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,4]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,2]]}},"alternative-id":["3860"],"URL":"https:\/\/doi.org\/10.1186\/ar4127","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717976186.793472773","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717976186.793472546","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717976186.793471732","asserted-by":"object"}]},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,4]]},"assertion":[{"value":"28 September 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R1"}}